The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the ...

Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Genentech, a Roche Group company (OTCQX:RHHBY) (OTCQX:RHHBF), said on Tuesday that a U.S. FDA advisory committee voted ...

Genentech, considered one of the biotech industry’s founding companies, plans to build a $700 million, 700,000-square-foot ...

HOLLY SPRINGS, N.C. -- Genentech, a leading biotechnology company based in San Francisco, is set to build a $700 million ...

Genentech plans to invest $700 million in a new facility in Holly Springs, North Carolina, creating 420 jobs and joining the ...

The biotech giant's new facility is part of a larger U.S. investment strategy, though it may roll back its buildout if the ...